Study to Evaluate the Efficacy and Safety of K-808 (Pemafibrate) in Participants With Primary Biliary Cholangitis (PBC) With Inadequate Response to Ursodeoxycholic Acid (UDCA) and/or Obeticholic Acid (OCA) Treatment.

Phase 2 Active not recruiting 46 enrolled Kowa Research Institute, Inc.

RandomizedParallel-groupQuadruple-blindTreatment

Study to investigate the efficacy and safety of two doses of K-808 (pemafribate) in subjects with PBC.

Evaluation	Drug	Modality	Dose	Route
Subject	K-877	Unknown	—	Oral